Core Viewpoint - Wheaton Precious Metals (WPM) stock is considered appealing yet unpredictable due to its high valuation, making it a challenging investment choice at the current price of approximately $76 [1][11]. Valuation Comparison - WPM stock has a price-to-sales (P/S) ratio of 30.5, significantly higher than the S&P 500's 2.8 [3] - The price-to-free cash flow (P/FCF) ratio for WPM is 39.1 compared to 17.6 for the S&P 500 [3] - WPM's price-to-earnings (P/E) ratio stands at 56.0, while the S&P 500's is 24.5 [3] Revenue Growth - WPM's revenues have grown at an average rate of 2.0% over the last three years, compared to 6.2% for the S&P 500 [4] - Revenues increased by 29.7% from $1.0 billion to $1.3 billion in the last 12 months, contrasting with a 5.3% growth for the S&P 500 [4] - Quarterly revenues rose by 38.1% to $381 million from $313 million a year prior, while the S&P 500 saw a 4.9% improvement [4] Profitability Metrics - WPM's operating income over the last four quarters reached $669 million, reflecting an operating margin of 55.0%, compared to 13.1% for the S&P 500 [5] - The operating cash flow (OCF) during this period was $950 million, indicating an OCF margin of 78.1%, compared to 15.7% for the S&P 500 [5] - WPM's net income was $609 million, suggesting a net income margin of 50.1%, while the S&P 500's margin is 11.3% [5] Financial Stability - WPM's debt stood at $5.7 million at the end of the most recent quarter, with a market capitalization of $36 billion, resulting in a debt-to-equity ratio of 0.0% compared to 21.5% for the S&P 500 [8] - Cash and cash equivalents account for $818 million of the total assets of $7.4 billion, leading to a cash-to-assets ratio of 9.4%, compared to 15.0% for the S&P 500 [8] Downturn Resilience - WPM stock has shown more resilience than the S&P 500 during recent downturns, with a notable decline of 43.8% during the inflation shock of 2022, compared to a 25.4% drop for the S&P 500 [10] - The stock fully rebounded to its pre-crisis peak by April 2023 and reached a high of $85.77 in May 2025 [10] - During the COVID pandemic, WPM stock fell 28.7%, recovering fully by April 2020, while the S&P 500 experienced a 33.9% decline [10] Overall Performance Assessment - WPM's performance across various parameters is rated as follows: Growth - Very Strong, Profitability - Extremely Strong, Financial Stability - Very Strong, Downturn Resilience - Strong, Overall - Very Strong [13]

Core Viewpoint - SkyWest (SKYW) has shown strong stock performance recently, with a +21.5% return over the past month, outperforming the S&P 500 composite's +9.9% and the Zacks Transportation - Airline industry's +21.8% [1] Earnings Estimate Revisions - SkyWest is expected to post earnings of $2.30 per share for the current quarter, reflecting a year-over-year increase of +26.4% [4] - The consensus earnings estimate for the current fiscal year is $9.28, indicating a +19.4% change from the previous year [4] - For the next fiscal year, the consensus estimate is $9.89, showing a +6.6% increase from the prior year [5] - The Zacks Rank for SkyWest is 2 (Buy), indicating a positive outlook based on recent changes in earnings estimates [6] Projected Revenue Growth - The consensus sales estimate for the current quarter is $977.68 million, representing a year-over-year increase of +12.8% [10] - For the current fiscal year, the revenue estimate is $3.9 billion, indicating a +10.5% change, while the next fiscal year's estimate is $4.06 billion, reflecting a +4.2% change [10] Last Reported Results and Surprise History - SkyWest reported revenues of $948.46 million in the last quarter, a year-over-year increase of +18% [11] - The EPS for the same period was $2.42, compared to $1.45 a year ago, with a surprise of +18.63% over the consensus estimate [11][12] Valuation - SkyWest is graded A on the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [16]

Gray Media (GTN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this broadcast television company have returned +38.1%, compared to the Zacks S&P 500 composite's +9.1% change. During this period, the Zacks Broadcast Radio and Television industry, which Gray Media falls in, has gained 18.5%. The key question now is: What could be the stock's future direc ...

Group 1 - The stock markets have rebounded significantly from post-April lows, suggesting a favorable environment for investors to reassess their holdings based on valuation metrics [1] - Gary Alexander has extensive experience in the technology sector, having worked on Wall Street and in Silicon Valley, which informs his insights into current industry trends [1] - Alexander has been a contributor to Seeking Alpha since 2017 and has been featured in various web publications, indicating his established presence in the investment community [1]

Core Viewpoint - Boston Scientific (BSX) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimate Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.72 per share, reflecting a year-over-year increase of +16.1% [5] - The Zacks Consensus Estimate for the current fiscal year is $2.91, indicating a year-over-year change of +15.9%, with a +2.2% revision over the last 30 days [5] - The consensus earnings estimate for the next fiscal year is $3.26, showing a change of +11.8% from the previous year, with a +0.9% revision over the past month [6] - Boston Scientific holds a Zacks Rank 2 (Buy), suggesting a favorable outlook based on recent earnings estimate changes [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.89 billion, indicating a year-over-year increase of +18.6% [11] - For the current fiscal year, the sales estimate is $19.49 billion, reflecting a change of +16.4%, while the next fiscal year's estimate is $21.55 billion, indicating a +10.6% change [11] Last Reported Results and Surprise History - In the last reported quarter, Boston Scientific achieved revenues of $4.66 billion, a year-over-year increase of +20.9%, and an EPS of $0.75 compared to $0.56 a year ago [12] - The company exceeded the Zacks Consensus Estimate for revenues by +2.31% and for EPS by +11.94% [12] - Boston Scientific has consistently beaten consensus EPS and revenue estimates over the past four quarters [13] Valuation - Boston Scientific is graded D on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17] - Valuation metrics such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [15][16] Bottom Line - The information presented suggests that Boston Scientific may outperform the broader market in the near term, supported by its Zacks Rank 2 [18]

Core Viewpoint - Arch Capital Group (ACGL) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimates - Arch Capital is expected to report earnings of $2.34 per share for the current quarter, reflecting a year-over-year decline of 9% [5] - The consensus earnings estimate for the current fiscal year is $7.89, indicating a year-over-year decrease of 15% [5] - For the next fiscal year, the consensus earnings estimate is $9.57, showing a year-over-year increase of 21.2% [6] - Over the last 30 days, the earnings estimates have seen slight changes of -1.8% for the current quarter and -0.1% for the current fiscal year [5][6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.68 billion, representing a year-over-year increase of 18.8% [11] - For the current fiscal year, the revenue estimate is $18.91 billion, indicating a growth of 13.8%, while the next fiscal year is projected at $20.32 billion, reflecting a growth of 7.5% [11] Last Reported Results and Surprise History - In the last reported quarter, Arch Capital achieved revenues of $4.56 billion, a year-over-year increase of 21.3% [12] - The EPS for the same period was $1.54, down from $2.45 a year ago, with a surprise of +12.41% compared to the consensus estimate [12][13] - The company has consistently beaten consensus EPS estimates in the last four quarters and topped revenue estimates three times [13] Valuation - Arch Capital has a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [7][18] - The Zacks Value Style Score for Arch Capital is graded B, indicating it is trading at a discount compared to its peers [17]

Core Viewpoint - Deere has been gaining attention in the market, with its stock performance outpacing the broader S&P 500 index and the farm equipment industry, raising questions about its future trajectory [2]. Earnings Estimates - Deere is expected to report earnings of $5.68 per share for the current quarter, reflecting a year-over-year decline of -33.4%. The consensus estimate for the current fiscal year is $18.89, indicating a -26.3% change [5][6]. - The consensus earnings estimate for the next fiscal year is $21.17, which represents a +12.1% increase compared to the previous year [6]. Revenue Projections - The consensus sales estimate for the current quarter is $10.65 billion, showing a year-over-year decrease of -21.8%. For the current and next fiscal years, the sales estimates are $38.23 billion and $40.52 billion, indicating changes of -14.6% and +6%, respectively [11]. Recent Performance - In the last reported quarter, Deere's revenues were $6.81 billion, down -35.1% year-over-year, with an EPS of $3.19 compared to $6.23 a year ago. The reported revenues fell short of the Zacks Consensus Estimate of $7.7 billion by -11.51% [12]. - The company has consistently beaten consensus EPS estimates in the last four quarters and has exceeded revenue estimates three times during this period [13]. Valuation Metrics - Deere's valuation metrics suggest it is trading at a premium compared to its peers, receiving a Zacks Value Style Score of D, indicating potential overvaluation [17].

Core Insights - Kroger Co. has experienced significant stock performance, with a share price increase of nearly 36% over the past year and an almost 20% rise in 2025 alone [1] Group 1 - The company's stock is trading near an all-time high [1] - The substantial increase in share price indicates strong market performance and investor confidence [1]

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

Core Viewpoint - Novo Nordisk's stock has experienced a decline of -2.2% over the past month, underperforming the Zacks S&P 500 composite's -0.5% change and the Zacks Large Cap Pharmaceuticals industry's -2% loss, raising questions about its near-term performance [1] Earnings Estimate Revisions - The consensus earnings estimate for the current quarter is $0.91 per share, reflecting a year-over-year increase of +9.6%, with a recent change of +2.2% over the last 30 days [4] - For the current fiscal year, the consensus earnings estimate is $3.85, indicating a +17.4% change from the previous year, with a +1.3% change in the last 30 days [4] - The next fiscal year's consensus earnings estimate is $4.71, showing a +22.4% change from the prior year, with a +2.1% change over the past month [5] - Novo Nordisk holds a Zacks Rank 3 (Hold), influenced by recent changes in consensus estimates and other earnings-related factors [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $11.33 billion, indicating a year-over-year increase of +19.1% [10] - The sales estimates for the current and next fiscal years are $50.66 billion and $58.15 billion, reflecting changes of +20.3% and +14.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Novo Nordisk achieved revenues of $12.26 billion, a year-over-year increase of +28.9%, and an EPS of $0.91 compared to $0.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $11.34 billion by +8.11%, and the EPS surprise was +9.64% [11] - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates twice and revenue estimates twice [12] Valuation - Novo Nordisk is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers [16]